ACLX - Arcellx, Inc.

114.3
0.250   0.219%

Share volume: 1,294,952
Last Updated: 03-04-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: 0.44%

PREVIOUS CLOSE
CHG
CHG%
$114.05
0.00
0.00%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
33%
Profitability 35%
Dept financing 27%
Liquidity 47%
Performance 30%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0.22%
1 Month
70.75%
3 Months
64.32%
6 Months
57.39%
1 Year
65.94%
2 Year
64.13%
Key data
Stock price
$114.30
P/E Ratio 
0.00
DAY RANGE
$114.07 - $114.65
EPS 
-$4.00
52 WEEK RANGE
$47.86 - $114.65
52 WEEK CHANGE
$66.62
MARKET CAP 
3.770 B
YIELD 
N/A
SHARES OUTSTANDING 
58.480 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
08-07-2025
BETA 
2.05
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$9,854,441
AVERAGE 30 VOLUME 
$4,218,031
Company detail
CEO: Rami Elghandour
Region: US
Website: arcellx.com
Employees: 80
IPO year: 2022
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Arcellx, Inc. engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM) It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins.

Recent news